738607-02-8

Basic information

• Product Name: Octanoic acid, 8-isocyano-2,2-dimethyl-8-[(4-methylphenyl)sulfonyl]-, ethyl ester
• CAS NO: 738607-02-8
• Molecular Formula: C20H29NO4S
• Molecular Weight: 379.521
• Mol File: 738607-02-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Octanoic acid, 8-isocyano-2,2-dimethyl-8-[(4-methylphenyl)sulfonyl]-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Octanoic acid, 8-isocyano-2,2-dimethyl-8-[(4-methylphenyl)sulfonyl]-, ethyl ester(738607-02-8)
• EPA Substance Registry System: Octanoic acid, 8-isocyano-2,2-dimethyl-8-[(4-methylphenyl)sulfonyl]-, ethyl ester(738607-02-8)

Safety Data

• Hazardous Substances Data: 738607-02-8(Hazardous Substances Data)

Upstream product

• 38622-91-2 [(p-methylphenyl)sulfonylmethyl]isonitrile 
• 123469-92-1 ethyl-2,2-dimethyl-7-bromoheptanoate 

Downstream Products

• 835925-54-7 1-[12-ethoxycarbonyl-6-isocyano-12-methyl-6-(toluene-4-sulfonyl)-tridecyl]-cyclopropanecarboxylic acid tert-butyl ester 

Relevant articles and documents

α-Cycloalkyl-substituted ω-keto-dicarboxylic acids as lipid regulating agents

A series of cycloalkyl-substituted oxo-alkanedicarboxylic acids have been prepared by the TosMIC methodology departing from haloalkyl-substituted cycloalkylcarboxylic esters. cyclopropyl derivatives showed IC50 activity in the 0.3-1.0 μM range

HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES

The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.